Potentially inappropriate medication in older participants of the Berlin Aging Study II (BASE-II) – Sex differences and associations with morbidity and medication use


Autoři: Sarah Toepfer aff001;  Juliane Bolbrinker aff002;  Maximilian König aff003;  Elisabeth Steinhagen-Thiessen aff001;  Reinhold Kreutz aff002;  Ilja Demuth aff001
Působiště autorů: Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Lipid Clinic at the Interdisciplinary Metabolism Center, Berlin, Germany aff001;  Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany aff002;  Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin, Charité-Universitätsmedizin, Berlin, Germany aff003;  Berlin Insitute of Health Center for Regenerative Therapies”oder ausführlicher „Charité—Universitätsmedizin Berlin, BCRT—Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany aff004
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.pone.0226511

Souhrn

Introduction

Multimorbidity in advanced age and the need for drug treatment may lead to polypharmacy, while pharmacokinetic and pharmacodynamic changes may increase the risk of adverse drug events (ADEs).

Objective

The aim of this study was to determine the proportion of subjects using potentially inappropriate medication (PIM) in a cohort of older and predominantly healthy adults in relation to polypharmacy and morbidity.

Methods

Cross-sectional data were available from 1,382 study participants (median age 69 years, IQR 67–71, 51.3% females) of the Berlin Aging Study II (BASE-II). PIM was classified according to the EU(7)-PIM and German PRISCUS (representing a subset of the former) list. Polypharmacy was defined as the concomitant use of at least five drugs. A morbidity index (MI) largely based on the Charlson Index was applied to evaluate the morbidity burden.

Results

Overall, 24.1% of the participants were affected by polypharmacy. On average, men used 2 (IQR 1–4) and women 3 drugs (IQR 1–5). According to PRISCUS and EU(7)-PIM, 5.9% and 22.6% of participants received at least one PIM, while use was significantly more prevalent in females (25.5%) compared to males (19.6%) considering EU(7)-PIM (p = 0.01). In addition, morbidity in males receiving PIM according to EU(7)-PIM was higher (median MI 1, IQR 1–3) compared to males without PIM use (median MI 1, IQR 0–2, p<0.001).

Conclusion

PIM use occurred more frequently in women than in men, while it was associated with higher morbidity in males. As expected, EU(7)-PIM identifies more subjects as PIM users than the PRISCUS list but further studies are needed to investigate the differential impact of both lists on ADEs and outcome.

Key points

We found PIM use to be associated with a higher number of regular medications and with increased morbidity. Additionally, we detected a higher prevalence of PIM use in females compared to males, suggesting that women and people needing intensive drug treatment are patient groups, who are particularly affected by PIM use.

Klíčová slova:

Age groups – Drug research and development – Drug therapy – Drugs – Elderly – Geriatrics – Kidneys – Morbidity


Zdroje

1. Calderon-Larranaga A, Poblador-Plou B, Gonzalez-Rubio F, Gimeno-Feliu LA, Abad-Diez JM, Prados-Torres A. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? Br J Gen Pract. 2012;62(605):e821–6. Epub 2012/12/06. doi: 10.3399/bjgp12X659295 23211262; PubMed Central PMCID: PMC3505415.

2. König M, Gollasch M, Demuth I, Steinhagen-Thiessen E. Prevalence of Impaired Kidney Function in the German Elderly: Results from the Berlin Aging Study II (BASE-II). Gerontology. 2017;63(3):201–9. Epub 2017/02/24. doi: 10.1159/000454831 28231583.

3. Vinkers CH, Tijdink JK, Luykx JJ, Vis R. [Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. Ned Tijdschr Geneeskd. 2012;155(35):A4900. Epub 2012/08/30. 22929751.

4. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157(14):1531–6. Epub 1997/07/28. 9236554.

5. Nothelle SK, Sharma R, Oakes A, Jackson M, Segal JB. Factors associated with potentially inappropriate medication use in community-dwelling older adults in the United States: a systematic review. Int J Pharm Pract. 2019. Epub 2019/04/10. doi: 10.1111/ijpp.12541 30964225.

6. Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31–32):543–51. Epub 2010/08/09. doi: 10.3238/arztebl.2010.0543 20827352; PubMed Central PMCID: PMC2933536.

7. Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31. Epub 2007/06/08. doi: 10.1007/s00228-007-0324-2 17554532.

8. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24. Epub 2003/12/10. doi: 10.1001/archinte.163.22.2716 14662625.

9. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–91. Epub 1997/02/01. 9033421; PubMed Central PMCID: PMC1226961.

10. Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861–75. Epub 2015/05/14. doi: 10.1007/s00228-015-1860-9 25967540; PubMed Central PMCID: PMC4464049.

11. Wallerstedt SM, Belfrage B, Fastbom J. Association between drug-specific indicators of prescribing quality and quality of drug treatment: a validation study. Pharmacoepidemiol Drug Saf. 2015;24(9):906–14. Epub 2015/07/07. doi: 10.1002/pds.3827 26147790; PubMed Central PMCID: PMC4758385.

12. Novaes PH, da Cruz DT, Lucchetti ALG, Leite ICG, Lucchetti G. Comparison of four criteria for potentially inappropriate medications in Brazilian community-dwelling older adults. Geriatr Gerontol Int. 2017;17(10):1628–35. Epub 2017/02/23. doi: 10.1111/ggi.12944 28224699.

13. Motter FR, Fritzen JS, Hilmer SN, Paniz EV, Paniz VMV. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;74(6):679–700. Epub 2018/03/29. doi: 10.1007/s00228-018-2446-0 29589066.

14. Schubert I, Kupper-Nybelen J, Ihle P, Thurmann P. Prescribing potentially inappropriate medication (PIM) in Germany's elderly as indicated by the PRISCUS list. An analysis based on regional claims data. Pharmacoepidemiol Drug Saf. 2013;22(7):719–27. Epub 2013/04/16. doi: 10.1002/pds.3429 23585247.

15. Endres HG, Kaufmann-Kolle P, Knopf H, Thurmann PA. [Which factors are associated with the use of potentially inadequate medications (PIM) in the elderly?: Results from the German health interview and examination survey (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(1):40–51. Epub 2017/11/16. doi: 10.1007/s00103-017-2654-2 29138901.

16. Pesch B, Dydak U, Lotz A, Casjens S, Quetscher C, Lehnert M, et al. Association of exposure to manganese and iron with relaxation rates R1 and R2*- magnetic resonance imaging results from the WELDOX II study. Neurotoxicology. 2018;64:68–77. Epub 2017/08/30. doi: 10.1016/j.neuro.2017.08.008 28847517; PubMed Central PMCID: PMC6358438.

17. Sonnerstam E, Sjolander M, Gustafsson M. An evaluation of the prevalence of potentially inappropriate medications in older people with cognitive impairment living in Northern Sweden using the EU(7)-PIM list. Eur J Clin Pharmacol. 2017;73(6):735–42. Epub 2017/03/02. doi: 10.1007/s00228-017-2218-2 28246889; PubMed Central PMCID: PMC5423959.

18. Bertram L, Böckenhoff A, Demuth I, Düzel S, Eckardt R, Li SC, et al. Cohort profile: The Berlin Aging Study II (BASE-II). Int J Epidemiol. 2014;43(3):703–12. Epub 2013/03/14. doi: 10.1093/ije/dyt018 23505255.

19. Gerstorf D, Bertram L, Lindenberger U, Pawelec G, Demuth I, Steinhagen-Thiessen E, et al. Editorial. Gerontology. 2016;62(3):311–5. Epub 2016/01/29. doi: 10.1159/000441495 26820471.

20. König M, Spira D, Demuth I, Steinhagen-Thiessen E, Norman K. Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II. J Gerontol A Biol Sci Med Sci. 2017;73(1):117–22. Epub 2017/05/10. doi: 10.1093/gerona/glx074 28481965.

21. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. Epub 2017/10/12. doi: 10.1186/s12877-017-0621-2 29017448; PubMed Central PMCID: PMC5635569.

22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. Epub 1987/01/01. doi: 10.1016/0021-9681(87)90171-8 3558716.

23. Meyer A, Salewsky B, Buchmann N, Steinhagen-Thiessen E, Demuth I. Relative Leukocyte Telomere Length, Hematological Parameters and Anemia—Data from the Berlin Aging Study II (BASE-II). Gerontology. 2016;62(3):330–6. Epub 2016/01/29. doi: 10.1159/000430950 26820977.

24. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71(12):1415–27. Epub 2015/09/27. doi: 10.1007/s00228-015-1954-4 26407687.

25. Linder R, Schneider U, Kothemann M, Verheyen F. [Physicians' prescription behavior of potentially inappropriate medications for elderly people: an analysis using the PRISCUS list based on TK routine data]. Dtsch Med Wochenschr. 2014;139(19):983–9. Epub 2014/05/02. doi: 10.1055/s-0034-1369948 24782150.

26. Heser K, Pohontsch NJ, Scherer M, Loffler A, Luck T, Riedel-Heller SG, et al. Perspective of elderly patients on chronic use of potentially inappropriate medication—Results of the qualitative CIM-TRIAD study. PLoS One. 2018;13(9):e0202068. Epub 2018/09/20. doi: 10.1371/journal.pone.0202068 30231027; PubMed Central PMCID: PMC6145513.

27. By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227–46. Epub 2015/10/09. doi: 10.1111/jgs.13702 26446832.

28. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. Epub 2014/10/18. doi: 10.1093/ageing/afu145 25324330; PubMed Central PMCID: PMC4339726.

29. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83. Epub 2008/01/26. doi: 10.5414/cpp46072 18218287.

30. Schwabe U, Paffrath D. Arzneiverordnungs-Report 2015.

31. Walker C. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac. Int J Rheumatol. 2018;2018:1302835. Epub 2019/01/12. doi: 10.1155/2018/1302835 30631366; PubMed Central PMCID: PMC6304524.

32. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. Epub 2011/01/13. doi: 10.1136/bmj.c7086 21224324; PubMed Central PMCID: PMC3019238.

33. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–92. Epub 2010/10/21. doi: 10.1001/jama.2010.1500 20959578; PubMed Central PMCID: PMC5142300.

34. Butler M, Nelson VA, Davila H, Ratner E, Fink HA, Hemmy LS, et al. Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann Intern Med. 2018;168(1):52–62. Epub 2017/12/20. doi: 10.7326/M17-1530 29255909.

35. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253–62. Epub 2008/11/20. doi: 10.1001/jama.2008.683 19017911; PubMed Central PMCID: PMC2823569.

36. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888–99. Epub 1999/06/17. doi: 10.1056/NEJM199906173402407 10369853.

37. Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV, et al. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019. Epub 2019/05/16. doi: 10.1016/j.ejim.2019.05.002 31084979.

38. Leonard CE, Han X, Brensinger CM, Bilker WB, Cardillo S, Flory JH, et al. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf. 2018;27(1):9–18. Epub 2017/11/07. doi: 10.1002/pds.4337 29108130; PubMed Central PMCID: PMC5770147.

39. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203. Epub 2008/10/24. doi: 10.2337/dc08-9025 18945920; PubMed Central PMCID: PMC2606813.

40. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551. Epub 2011/08/04. doi: 10.1136/bmj.d4551 21810886; PubMed Central PMCID: PMC3149102.

41. Abu Sin M, Askar M, Beermann S, Bertz J, Buda S, Busch M. Gesundheit in Deutschland, GESUNDHEITSBERICHTERSTATTUNG DES BUNDES GEMEINSAM GETRAGEN VON RKI UND DESTATIS. 2015.

42. Kachru N, Carnahan RM, Johnson ML, Aparasu RR. Potentially inappropriate anticholinergic medication use in community-dwelling older adults: a national cross-sectional study. Drugs Aging. 2015;32(5):379–89. Epub 2015/04/03. doi: 10.1007/s40266-015-0257-x 25832970.

43. Miller GE, Sarpong EM, Davidoff AJ, Yang EY, Brandt NJ, Fick DM. Determinants of Potentially Inappropriate Medication Use among Community-Dwelling Older Adults. Health Serv Res. 2017;52(4):1534–49. Epub 2016/10/01. doi: 10.1111/1475-6773.12562 27686781; PubMed Central PMCID: PMC5517671.

44. Saum KU, Schottker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, et al. Is Polypharmacy Associated with Frailty in Older People? Results From the ESTHER Cohort Study. J Am Geriatr Soc. 2017;65(2):e27–e32. Epub 2016/12/27. doi: 10.1111/jgs.14718 28024089.

45. Kristensen RU, Norgaard A, Jensen-Dahm C, Gasse C, Wimberley T, Waldemar G. Changes in the Prevalence of Polypharmacy in People with and without Dementia from 2000 to 2014: A Nationwide Study. J Alzheimers Dis. 2019;67(3):949–60. Epub 2019/01/29. doi: 10.3233/JAD-180427 30689562.

46. Oktora MP, Denig P, Bos JHJ, Schuiling-Veninga CCM, Hak E. Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States. PLoS One. 2019;14(3):e0214240. Epub 2019/03/23. doi: 10.1371/journal.pone.0214240 30901377; PubMed Central PMCID: PMC6430511.

47. Molokhia M, Majeed A. Current and future perspectives on the management of polypharmacy. BMC Fam Pract. 2017;18(1):70. Epub 2017/06/08. doi: 10.1186/s12875-017-0642-0 28587644; PubMed Central PMCID: PMC5461681.

48. Martinot P, Landre B, Zins M, Goldberg M, Ankri J, Herr M. Association Between Potentially Inappropriate Medications and Frailty in the Early Old Age: A Longitudinal Study in the GAZEL Cohort. J Am Med Dir Assoc. 2018;19(11):967–73 e3. Epub 2018/09/03. doi: 10.1016/j.jamda.2018.07.008 30172683.

49. Hedna K, Hakkarainen KM, Gyllensten H, Jonsson AK, Petzold M, Hagg S. Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. Eur J Clin Pharmacol. 2015;71(12):1525–33. Epub 2015/09/27. doi: 10.1007/s00228-015-1950-8 26407684; PubMed Central PMCID: PMC4643104.

50. Reich O, Rosemann T, Rapold R, Blozik E, Senn O. Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalization. PLoS One. 2014;9(8):e105425. Epub 2014/08/20. doi: 10.1371/journal.pone.0105425 25136981; PubMed Central PMCID: PMC4138178.

51. Abraham O, Schleiden L, Albert SM. Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep. Int J Clin Pharm. 2017;39(4):808–17. Epub 2017/05/04. doi: 10.1007/s11096-017-0467-x 28466395; PubMed Central PMCID: PMC5541127.


Článok vyšiel v časopise

PLOS One


2019 Číslo 12